EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat

Hong-Fei Wang, Yu-Cheng Mao, Su-Fen Qi, Xin-Yi Xu, Zi-Yan Zhang, Chang Geng, Kai Song, Qing-Bao Tian

American Journal of Cardiovascular Drugs · 2024

DOI: 10.1007/s40256-024-00651-7 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift American Journal of Cardiovascular Drugs, 2024. Verfasst von Hong-Fei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Cholesterol, LDL, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The objective of this investigation is to examine the benefits and potential risks of these drugs in individuals by varying baseline low-density lipoprotein cholesterol (LDL-C) values, utilizing the concept of the number needed to treat (NNT). METHODS: We extensively searched electronic databases, such as PubMed, EMBASE, Cochrane, and Web of Science, up to 6 August 2023. Baseline LDL-C values were stratified into four categories: < 100, 100-129, 130-159, and ≥ 160 mg/dL. Risk ratios (RRs) and NNT values were computed. RESULTS: This analysis incorporated data from 46 randomized controlled trials (RCTs), encompassing a total of 237,870 participants. The meta-regression analysis demonstrated an incremental diminishing risk of major adverse cardiovascular events (MACE) with increasing baseline LDL-C values. Statins exhibited a significant reduction in MACE [number needed to treat to benefit (NNTB) 31, 95% confidence interval (CI) 25-37], but this effect was observed only in individuals with baseline LDL-C values of 100 mg/dL or higher. Ezetimibe and PCSK9 inhibitors also were effective in reducing MACE (NNTB 18, 95% CI 11-41, and NNTB 18, 95% CI 16-24). Notably, the safety outcomes of statins and ezetimibe did not reach statistical significance, while the incidence of injection-site reactions with PCSK9 inhibitors was statistically significant [number needed to treat to harm (NNTH) 41, 95% CI 80-26]. CONCLUSION: Statins, ezetimibe, and PCSK9 inhibitors demonstrated a substantial capacity to reduce MACE, particularly among individuals whose baseline LDL-C values were relatively higher. The NNT visually demonstrates the gradient between baseline LDL-C and cardiovascular disease (CVD) risk. SYSTEMATIC REVIEW REGISTRATION: Registration: PROSPERO identifier number: CRD42023458630.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLCardiovascular DiseasesHumansRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsNumbers Needed To TreatEzetimibeAnticholesteremic AgentsPCSK9 InhibitorsRisk AssessmentAdult

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsEzetimibeAnticholesteremic AgentsPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Shijiazhuang, China.
  • Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, China.
  • Postdoctoral Research Station in Basic Medicine, Hebei Medical University, Shijiazhuang, China.
  • School of Nursing, Hebei Medical University, Shijiazhuang, China.
  • Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Shijiazhuang, China. tqb1980@hebmu.edu.cn.
  • Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, China. tqb1980@hebmu.edu.cn.

Zitieren

APA

Wang, H. F., Mao, Y. C., Qi, S. F., Xu, X. Y., Zhang, Z. Y., Geng, C., Song, K., & Tian, Q. B. (2024). Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-024-00651-7

Vancouver

Wang HF, Mao YC, Qi SF, Xu XY, Zhang ZY, Geng C, et al. Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat. American Journal of Cardiovascular Drugs. 2024. doi:10.1007/s40256-024-00651-7

BibTeX
@article{Wang2024,
  author = {Wang, Hong-Fei and Mao, Yu-Cheng and Qi, Su-Fen and Xu, Xin-Yi and Zhang, Zi-Yan and Geng, Chang and Song, Kai and Tian, Qing-Bao},
  title = {Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2024},
  doi = {10.1007/s40256-024-00651-7}
}
Kostenlos starten →